PURPOSE: High-grade gliomas of the CNS are characterized by poor treatment response and prognosis for long-term survival. The Children's Oncology Group (COG) L991 study investigated the neuropsychological, behavioral, and quality of life (QoL) outcomes after treatment on the Children's Cancer Group (CCG) trial for high-grade gliomas (CCG-945). PATIENTS AND METHODS: Fifty-four patients (29 males, 25 females) with a median age of 8.8 years at diagnosis (range, 0.2 to 19.5 years) were enrolled at 25 institutions in North America, representing 81% of available survivors; median length of follow-up was 15.1 years (range, 9.5 to 19.2 years), and median age at study evaluation was 23.6 years (range, 11.3 to 36 years). Standardized tests of neuropsychological functioning and QoL were performed. Descriptive statistics summarized principal findings, and one-way analysis of variance identified potential predictors of outcomes. RESULTS: With an average follow-up time of 15 years, survivors demonstrated intellectual functioning within the low-average range. Executive functioning and verbal memory were between the low-average and borderline ranges. In contrast, visual memory and psychomotor processing speed were between the borderline and impaired ranges, respectively. Approximately 75% of patient reported overall QoL within or above normal limits for both physical and psychosocial domains. Nonhemispheric tumor location (midline or cerebellum), female sex, and younger age at treatment emerged as independent risk factors. CONCLUSION: These results serve as a benchmark for comparison with future pediatric high-grade glioma studies, in addition to identifying at-risk cohorts that warrant further research and proactive interventions to minimize late effects while striving to ensure survival.
RCT Entities:
PURPOSE: High-grade gliomas of the CNS are characterized by poor treatment response and prognosis for long-term survival. The Children's Oncology Group (COG) L991 study investigated the neuropsychological, behavioral, and quality of life (QoL) outcomes after treatment on the Children's Cancer Group (CCG) trial for high-grade gliomas (CCG-945). PATIENTS AND METHODS: Fifty-four patients (29 males, 25 females) with a median age of 8.8 years at diagnosis (range, 0.2 to 19.5 years) were enrolled at 25 institutions in North America, representing 81% of available survivors; median length of follow-up was 15.1 years (range, 9.5 to 19.2 years), and median age at study evaluation was 23.6 years (range, 11.3 to 36 years). Standardized tests of neuropsychological functioning and QoL were performed. Descriptive statistics summarized principal findings, and one-way analysis of variance identified potential predictors of outcomes. RESULTS: With an average follow-up time of 15 years, survivors demonstrated intellectual functioning within the low-average range. Executive functioning and verbal memory were between the low-average and borderline ranges. In contrast, visual memory and psychomotor processing speed were between the borderline and impaired ranges, respectively. Approximately 75% of patient reported overall QoL within or above normal limits for both physical and psychosocial domains. Nonhemispheric tumor location (midline or cerebellum), female sex, and younger age at treatment emerged as independent risk factors. CONCLUSION: These results serve as a benchmark for comparison with future pediatric high-grade glioma studies, in addition to identifying at-risk cohorts that warrant further research and proactive interventions to minimize late effects while striving to ensure survival.
Authors: Raymond K Mulhern; Holly A White; John O Glass; Larry E Kun; Laurie Leigh; Stephen J Thompson; Wilburn E Reddick Journal: J Int Neuropsychol Soc Date: 2004-03 Impact factor: 2.892
Authors: Michael A Fearing; Erin D Bigler; Elisabeth A Wilde; Jamie L Johnson; Jill V Hunter; Gerri Hanten; Harvey S Levin Journal: J Child Neurol Date: 2008-07 Impact factor: 1.987
Authors: Maryam Fouladi; Daniel L Hunt; Ian F Pollack; Gregor Dueckers; Peter C Burger; Laurence E Becker; Allen J Yates; Floyd H Gilles; Richard L Davis; James M Boyett; Jonathan L Finlay Journal: Cancer Date: 2003-09-15 Impact factor: 6.860
Authors: W Lin; Q Zhu; W Gao; Y Chen; C-H Toh; M Styner; G Gerig; J K Smith; B Biswal; J H Gilmore Journal: AJNR Am J Neuroradiol Date: 2008-09-10 Impact factor: 3.825
Authors: J H Wisoff; J M Boyett; M S Berger; C Brant; H Li; A J Yates; P McGuire-Cullen; P A Turski; L N Sutton; J C Allen; R J Packer; J L Finlay Journal: J Neurosurg Date: 1998-07 Impact factor: 5.115
Authors: Roger J Packer; James G Gurney; Judy A Punyko; Sarah S Donaldson; Peter D Inskip; Marilyn Stovall; Yutaka Yasui; Ann C Mertens; Charles A Sklar; H Stacy Nicholson; Lonnie K Zeltzer; Joseph P Neglia; Leslie L Robison Journal: J Clin Oncol Date: 2003-09-01 Impact factor: 50.717
Authors: Sumedh Subodh Shah; Anna Dellarole; Eric Cecala Peterson; Amade Bregy; Ricardo Komotar; Philip D Harvey; Mohamed Samy Elhammady Journal: Childs Nerv Syst Date: 2015-03-01 Impact factor: 1.475
Authors: Andge Valiakhmetova; Sergey Gorelyshev; Alexander Konovalov; Yuri Trunin; Alexander Savateev; David E Kram; Eric Severson; Amanda Hemmerich; Claire Edgerly; Daniel Duncan; Nicholas Britt; Richard S P Huang; Julia Elvin; Vincent Miller; Jeffrey S Ross; Laurie Gay; Joshua McCorkle; Andrew Rankin; Rachel L Erlich; Yakov Chudnovsky; Shakti H Ramkissoon Journal: Oncologist Date: 2019-10-16
Authors: Lillian Sung; Theo Zaoutis; Nicole J Ullrich; Donna Johnston; Lee Dupuis; Elena Ladas Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167
Authors: Heather M Conklin; Jason M Ashford; Marcos Di Pinto; Christopher G Vaughan; Gerard A Gioia; Thomas E Merchant; Robert J Ogg; Victor Santana; Shengjie Wu Journal: J Neurooncol Date: 2013-03-25 Impact factor: 4.130
Authors: Lisa S Kahalley; Heather M Conklin; Vida L Tyc; Melissa M Hudson; Stephanie J Wilson; Shengjie Wu; Xiaoping Xiong; Pamela S Hinds Journal: Psychooncology Date: 2013-02-28 Impact factor: 3.894